REG - Beximco Pharmaceut - Board Changes

Beximco PharmaceuticalsAnnouncement

18/01/2021 07:00

RNS Number : 9357L
  
Beximco Pharmaceuticals Ltd
  
18 January 2021
  
 

18 January 2021
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
BEXIMCO PHARMACEUTICALS LTD. 
 
Board Changes
 
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces it has appointed Dr. Md. Ibraheem Hosein Khan as an Independent Director of the Company, with immediate effect. Dr. Khan will replace Shah Monjurul Hoque who is retiring from the Board on completion of his statutory tenure of two consecutive terms of three years each.
 
Dr. Md. Ibraheem Hosein Khan, before his retirement from service in the Bangladesh Government, worked in a number of different Government departments including the Prime Minister's Office, Ministry of Land and Ministry of Cultural Affairs. Dr. Khan has also served as Administrator for the Dhaka South City Corporation. Dr. Khan holds a PhD from Jahangirnagar University, Dhaka, two master's degrees and two bachelor's degrees from institutions in Bangladesh, Australia and the United Kingdom.
 
Mr. A S F Rahman - Chairman of the Board of Directors of Beximco Pharmaceuticals, commented:
 
"I am delighted that Dr. Ibraheem has agreed to join the Board. He brings extensive experience and knowledge, which will be invaluable to the Company as we continue to implement our growth strategy across the domestic and international markets. On behalf of the Company, I would like to thank Shah Monjurul Hoque for his valuable contribution to the Company and wish him well in the future"
 
Additional disclosure information required by Schedule 2(g) of the AIM Rules for Companies
 
Dr. Md. Ibraheem Hosein Khan
 
Aside from his appointment to the Board, Dr. Md. Ibraheem Hosein Khan, aged 61, does not currently hold and has not held any directorships or partnerships in the past five years:
 
Dr. Khan does not have any direct or indirect interest in the issued share capital of the Company.
 
 
For further information please visit www.beximcopharma.com or enquire to: 
 



Beximco Pharma




Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
 




Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, ext.20030
 




Mohammad Asad Ullah, FCS, Executive Director & Company Secretary
Tel: +880 2 58611891, +880 2 58612040, Ext. 10140
 




SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
 




SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
 




FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
 



 
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
 
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOAUBVSRASUAAAR